Cell therapy for central nervous system disorders: Current obstacles to progress

Takao Yasuhara, Satoshi Kawauchi, Kyohei Kin, Jun Morimoto, Masahiro Kameda, Tatsuya Sasaki, Brooke Bonsack, Chase Kingsbury, Naoki Tajiri, Cesario V. Borlongan, Isao Date

Research output: Contribution to journalReview article

Abstract

Cell therapy for disorders of the central nervous system has progressed to a new level of clinical application. Various clinical studies are underway for Parkinson's disease, stroke, traumatic brain injury, and various other neurological diseases. Recent biotechnological developments in cell therapy have taken advantage of the technology of induced pluripotent stem (iPS) cells. The advent of iPS cells has provided a robust stem cell donor source for neurorestoration via transplantation. Additionally, iPS cells have served as a platform for the discovery of therapeutics drugs, allowing breakthroughs in our understanding of the pathology and treatment of neurological diseases. Despite these recent advances in iPS, adult tissue-derived mesenchymal stem cells remain the widely used donor for cell transplantation. Mesenchymal stem cells are easily isolated and amplified toward the cells' unique trophic factor-secretion property. In this review article, the milestone achievements of cell therapy for central nervous system disorders, with equal consideration on the present translational obstacles for clinic application, are described.

Original languageEnglish
JournalCNS Neuroscience and Therapeutics
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Induced Pluripotent Stem Cells
Central Nervous System Diseases
Cell- and Tissue-Based Therapy
Mesenchymal Stromal Cells
Cell Transplantation
Drug Discovery
Parkinson Disease
Stem Cells
Transplantation
Stroke
Pathology
Technology
Therapeutics

Keywords

  • cell therapy
  • iPS cells
  • Parkinson's disease
  • stroke
  • traumatic brain injury

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Physiology (medical)
  • Pharmacology (medical)

Cite this

Cell therapy for central nervous system disorders : Current obstacles to progress. / Yasuhara, Takao; Kawauchi, Satoshi; Kin, Kyohei; Morimoto, Jun; Kameda, Masahiro; Sasaki, Tatsuya; Bonsack, Brooke; Kingsbury, Chase; Tajiri, Naoki; Borlongan, Cesario V.; Date, Isao.

In: CNS Neuroscience and Therapeutics, 01.01.2019.

Research output: Contribution to journalReview article

Yasuhara, Takao ; Kawauchi, Satoshi ; Kin, Kyohei ; Morimoto, Jun ; Kameda, Masahiro ; Sasaki, Tatsuya ; Bonsack, Brooke ; Kingsbury, Chase ; Tajiri, Naoki ; Borlongan, Cesario V. ; Date, Isao. / Cell therapy for central nervous system disorders : Current obstacles to progress. In: CNS Neuroscience and Therapeutics. 2019.
@article{811be079573a4aeabe6f17fc78e6047d,
title = "Cell therapy for central nervous system disorders: Current obstacles to progress",
abstract = "Cell therapy for disorders of the central nervous system has progressed to a new level of clinical application. Various clinical studies are underway for Parkinson's disease, stroke, traumatic brain injury, and various other neurological diseases. Recent biotechnological developments in cell therapy have taken advantage of the technology of induced pluripotent stem (iPS) cells. The advent of iPS cells has provided a robust stem cell donor source for neurorestoration via transplantation. Additionally, iPS cells have served as a platform for the discovery of therapeutics drugs, allowing breakthroughs in our understanding of the pathology and treatment of neurological diseases. Despite these recent advances in iPS, adult tissue-derived mesenchymal stem cells remain the widely used donor for cell transplantation. Mesenchymal stem cells are easily isolated and amplified toward the cells' unique trophic factor-secretion property. In this review article, the milestone achievements of cell therapy for central nervous system disorders, with equal consideration on the present translational obstacles for clinic application, are described.",
keywords = "cell therapy, iPS cells, Parkinson's disease, stroke, traumatic brain injury",
author = "Takao Yasuhara and Satoshi Kawauchi and Kyohei Kin and Jun Morimoto and Masahiro Kameda and Tatsuya Sasaki and Brooke Bonsack and Chase Kingsbury and Naoki Tajiri and Borlongan, {Cesario V.} and Isao Date",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/cns.13247",
language = "English",
journal = "CNS Neuroscience and Therapeutics",
issn = "1755-5930",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Cell therapy for central nervous system disorders

T2 - Current obstacles to progress

AU - Yasuhara, Takao

AU - Kawauchi, Satoshi

AU - Kin, Kyohei

AU - Morimoto, Jun

AU - Kameda, Masahiro

AU - Sasaki, Tatsuya

AU - Bonsack, Brooke

AU - Kingsbury, Chase

AU - Tajiri, Naoki

AU - Borlongan, Cesario V.

AU - Date, Isao

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Cell therapy for disorders of the central nervous system has progressed to a new level of clinical application. Various clinical studies are underway for Parkinson's disease, stroke, traumatic brain injury, and various other neurological diseases. Recent biotechnological developments in cell therapy have taken advantage of the technology of induced pluripotent stem (iPS) cells. The advent of iPS cells has provided a robust stem cell donor source for neurorestoration via transplantation. Additionally, iPS cells have served as a platform for the discovery of therapeutics drugs, allowing breakthroughs in our understanding of the pathology and treatment of neurological diseases. Despite these recent advances in iPS, adult tissue-derived mesenchymal stem cells remain the widely used donor for cell transplantation. Mesenchymal stem cells are easily isolated and amplified toward the cells' unique trophic factor-secretion property. In this review article, the milestone achievements of cell therapy for central nervous system disorders, with equal consideration on the present translational obstacles for clinic application, are described.

AB - Cell therapy for disorders of the central nervous system has progressed to a new level of clinical application. Various clinical studies are underway for Parkinson's disease, stroke, traumatic brain injury, and various other neurological diseases. Recent biotechnological developments in cell therapy have taken advantage of the technology of induced pluripotent stem (iPS) cells. The advent of iPS cells has provided a robust stem cell donor source for neurorestoration via transplantation. Additionally, iPS cells have served as a platform for the discovery of therapeutics drugs, allowing breakthroughs in our understanding of the pathology and treatment of neurological diseases. Despite these recent advances in iPS, adult tissue-derived mesenchymal stem cells remain the widely used donor for cell transplantation. Mesenchymal stem cells are easily isolated and amplified toward the cells' unique trophic factor-secretion property. In this review article, the milestone achievements of cell therapy for central nervous system disorders, with equal consideration on the present translational obstacles for clinic application, are described.

KW - cell therapy

KW - iPS cells

KW - Parkinson's disease

KW - stroke

KW - traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=85074355038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074355038&partnerID=8YFLogxK

U2 - 10.1111/cns.13247

DO - 10.1111/cns.13247

M3 - Review article

C2 - 31622035

AN - SCOPUS:85074355038

JO - CNS Neuroscience and Therapeutics

JF - CNS Neuroscience and Therapeutics

SN - 1755-5930

ER -